Opko Health, Inc. · NASDAQ:OPK
Opko Health — Investor Presentation (March 2024)
23 slides from Opko Health's investor presentation, Mar 28, 2024
Slide 1: Corporate Presentation March 2024
OPKO Corporate Presentation MARCH 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking taterents Rs pearaton conan Yrariokng stents a8 Oat cafe vet e Pt Sein Laon Rtn At of 185 (SARA in ented by words be subject othe saecarbr provision fhe PSLRA Industry an Market Oata Int nd rf a ne met pennation tae ben ed fom bd pry ny pions ad seg pet yma
Slide 3: Building a leading portfolio of next-generation therapies in fast-growing segments
Building a leading portfolio of next-generation therapies in fast-growing segments es GROWING COMMERCIAL HGH FRANCHISE NGENLA™ long-acting efficacy to reshape the market Estimated $85.5 billion market expected to expand by upto 12.3% annually between 2023-2030" Proudly partnered wh Pzer Lofeer VALUE
Slide 4: Leadership team with unprecedented experience
Leadership team with unprecedented experience 9.9 & 2 F Phil Frost Jane Hsiao Elias Zerhouni Gary Nabel John Mascola CEO andChaleman Chief Technical PresidentandVice —Grerlansration _-_—_ Chief Scientitle Officer and View Chairman i Officer, Medex fenecnormuaans Chama Officer and Director anor Fomer
Slide 5: Addressing Established Markets with Next-Generation Solutions
Addressing Established Markets with Next-Generation Solutions DISEASE HUMAN GROWTH SOLID TUMOR LEUKEMIA AND INFECTIOUS AREA HORMONE DEFICIENCY CANCERS LYMPHOMAS. DISEASES. te $5 5p 980,000- 140,000: 95% LoeaL ANNUAL, ANNUAL oF GLOBAL, MaRKer us-eases? us-enses? rorutamion mrecreD ‘WIT EBV ALONE? unm
Slide 6: Expanding OPKO's global footprint through partnerships
Expanding OPKO’s global footprint through partnerships Pfizer EP MERCK YH wornnsgnyanagencn (2) INIH)) pis INDUSTRY- LEADING PARTNERS Track record of partnering with world-leading organizations on attractive terms SOUGHT OUT ‘SCIENCE OPKO's scientific RISK- AND. COST-SHARING Agreements allow THINKIN
Slide 7: Preparing for global rollouts and offsetting R&D costs with industry-leading partners
Preparing for global rollouts and offsetting R&D costs with industry-leading partners =) Pfizer NGENLA™ ELIGIBLE FOR ADDITIONAL, *100m IN MILESTONE PAYMENTS FOR ADDITIONAL INDICATIONS AND GROSS. PROFIT SHARE ON GLOBAL SALES $ PAYMENT IN 2028 & merck EBV NANOPARTICLE VACCINE ELIGIBLE FORUP TO °872.5M
Slide 8: Robust pipeline for well-understood diseases in need of next-generation treatments
Robust pipeline for well-understood diseases in need of next-generation treatments ‘Geuth Homone Otay = Pest 2 ‘outa Hormone Dotcaney ena Seon ‘her Peiticindeatons Tetraspecife LASER Teoatentet Leukemastynphora Mulspecite Immune Hematlei a ee 23 Be ES —_ Pras Pec on EBV Nanoparticle _revertonfEBVeoe
Slide 9: Focus on fast-growing markets with differentiated next-generation therapies
Focus on fast-growing markets with differentiated next-generation therapies WE BELIEVE NGENLA™ IS POSITIONED TO GAIN SIGNIFICANT U.S. AND WORLDWIDE SHARE Berrer Growin NexT.ceN provoty ADHERENCE GLOBAL innovarion PARTNERED MARKET FOR CHILOREN WITH PFIZER Market to consoate Estimated. bition “i trom
Slide 10: Next-generation NGENLA poised to capture significant share of growing global market
Next-generation NGENLA™ poised to capture significant share of growing global market EXPANDING SHARE OF GROWING MARKET TODAY FUTURE CURRENT MARKET a Maret expetegto grow by upto 12.3% 55568 $ ‘annually due to yew america .OB Sveterachrence ‘oweetyweatment Estimated global git market in 2022" 2022 20
Slide 11: Continued upside from Pfizer partnership in 2024 and beyond
Continued upside from Pfizer partnership in 2024 and beyond INDICATION status ‘Growth Hormone Deficiency (Pesiatic) AMMA Growth Hormone GLOBAL REGISTRATION STRATEGIES Deficiency (Aduits) — UTTIarsr7.Ng Other pediatric ther peck PHASES e Pfizer US. and Eupean approval of adut Indication would Unoek a
Slide 12: Innovation Pipeline
Innovation Pipeline
Slide 13: Proprietary approaches with broad disease applicability
Proprietary approaches with broad disease applicability IMMUNO- GneoLocy INFECTIOUS DISEASE ‘Strong IP around core fr pe fr fi _— And Ad Broad optionalty in diseases ‘not addressable by older, modaities | 4 | 4 ‘Strong synergies across Muttispecific antioodies —-Muttspeciic antibodies Nentyatent Ean
Slide 14: Addressing large and critical patient needs in oncology
Addressing large and critical patient needs in oncology with therapies that attack multiple disease drivers LS ESTABLISHED GLOBAL MARKETS NEXT-GENERATION THERAPIES WITH UNMET EES ooo ‘io Ten angen and we or agen SOLID TUMORS* BLOOD caNceRs** $ $ 1858 258 PROVEN TECHNOLOGIES 300k 288k BREAST PROSTATE
Slide 15: Tetraspecific LASER Antibodies for Immuno-Oncology
Tetraspecific LASER Antibodies for Immuno-Oncology LUNG, PROSTATE, BREAST, UTERINE, B CELL MALIGNANCIES: COLON AND OTHER SOLID CANCERS LYMPHOMAILEUKEMIA Lead candidate with IND MDx2001 InINO-enabling phase Mpx2003 submission expected in First Half 2024 ual T-cell signaling com stimulates T cells via
Slide 16: Tackling EBV, one of the world's most common viruses
Tackling EBV, one of the world’s most common viruses with no approved vaccines or therapies es NEXT-GENERATION THERAPIES ESTABLISHED GLOBAL MARKETS WITH UNMET NEED Nanoparticle £6 ‘anatetorgeing fur ‘raiprotene 8% OF GLOBAL POPULATION — INFECTED BY ADULTHOOD" PROVEN TECHNOLOGIES MERCK 265,000 163,00
Slide 17: Improving treatment of infectious disease through multispecifics that address viral evolution
Improving treatment of infectious disease through multispecifics that address viral evolution NEXT-GENERATION THERAPIES OO —_Mutispecinc long-acting antibodies platform allows forthe rational Selection of multiple targets designed to overcome drug ‘resistance and prevent viral escape PROVEN TECHNOLO
Slide 18: Diagnostics Restructuring
Diagnostics Restructuring
Slide 19: Divesting select clinical diagnostic services assets
Divesting select clinical diagnostic services assets Entered into definitive agreement with LabCorp for $237.5 million + Transaction includes certain laboratory testing businesses focused on clinical diagnostics and women's health + Select patient service centers, customer contracts and operating as
Slide 20: Continued focus on improving profitability through strategic reorganization and cost reduction
Continued focus on improving profitability through strategic reorganization and cost reduction IuPROVING PRODUCTIVITY EXPANDING SERVICE LINES eecRECIALTY TESTING, ait ENHANCING INNOUATION THROUGH EXISTING OFFER 8 IWnighvave SpeclaLTY SaPaBnuTies TESTING SEGMENTS BESTIN-CLASS ONCOLOGY TESTING PORTFOL
Slide 21: Operating Businesses
Operating Businesses
Slide 22: Operating units generating additional income for reinvestment
Operating units generating additional income for reinvestment IRELAND GLOBALFINANCIALS. $863.5m Us. TOTAL SALES $ 31.0m RAYALOEE SALES MEXICO TOTAL SALES BY COUNTRY ISRAEL US.:$597.8M Spain: $23.5M Ireland: $141.5M Israel: $9.70 Chile: $68.2 Other: $22 Mexico: $20.2 CHILE vw?
Slide 23: Thank you
Thank you